Altimmune (NASDAQ:ALT) Given Market Perform Rating at William Blair

William Blair restated their market perform rating on shares of Altimmune (NASDAQ:ALT) in a report published on Friday,RTT News reports.

A number of other brokerages have also commented on ALT. Stifel Nicolaus started coverage on shares of Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Altimmune Stock Performance

Shares of NASDAQ:ALT opened at $5.92 on Friday. The firm has a market cap of $455.92 million, a PE ratio of -3.82 and a beta of 0.87. The firm’s fifty day moving average is $6.48 and its 200-day moving average is $7.12. Altimmune has a 52 week low of $5.14 and a 52 week high of $11.16.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. Sell-side analysts forecast that Altimmune will post -1.35 EPS for the current year.

Insider Buying and Selling

In related news, CFO Gregory L. Weaver purchased 10,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Altimmune

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. increased its stake in Altimmune by 35.6% in the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock valued at $37,888,000 after purchasing an additional 1,378,854 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Altimmune by 4.7% during the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after acquiring an additional 74,194 shares in the last quarter. Bellevue Group AG raised its holdings in shares of Altimmune by 9.5% in the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock worth $6,817,000 after acquiring an additional 81,786 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Altimmune by 5.7% in the 4th quarter. Northern Trust Corp now owns 665,916 shares of the company’s stock worth $4,801,000 after acquiring an additional 35,918 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of Altimmune by 33.2% in the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock worth $4,364,000 after acquiring an additional 151,001 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.